Therapeutic Prostate Cancer Peptide Vaccine TENDU

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A peptide cancer vaccine, based on the tetanus-epitope targeting (TET)-platform, composed of as of yet undisclosed tumor-associated antigens (TAAs) that are specific for prostate cancer and a tetanus-based vaccine adjuvant in the same molecule, with potential immunomodulating and antineoplastic activities. Upon administration, therapeutic prostate cancer peptide vaccine TENDU may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against prostate cancer cells that express these TAAs, resulting in tumor cell lysis. The tetanus peptide may enhance the anti-tumor immune response.

**Synonyms:** - TENDU - TENDU Vaccine - TET-based Prostate Cancer Peptide Vaccine TENDU - Tetanus-epitope-targeting-based Prostate Cancer Peptide Vaccine TENDU